ATTO Stock Forecast: Attovia Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Attovia Therapeutics, Inc. is $45. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 4 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Attovia Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (49): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Volatility (2): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ATTO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ATTO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 1 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Nov 2026 | Citigroup | Maintains | Buy | — |
| 10 Nov 2026 | Morgan Stanley | Maintains | Overweight | — |
| 31 Aug 2026 | Citigroup | Initiates | Buy | — |
| 31 Aug 2026 | Leerink Partners | Initiates | Outperform | — |
| 31 Aug 2026 | LifeSci Capital | Initiates | Outperform | — |
| 31 Aug 2026 | Morgan Stanley | Initiates | Overweight | — |
| 31 Aug 2026 | RBC Capital | Initiates | Outperform | — |
| 15 Aug 2022 | Barrington Research | Maintains | Outperform | $32 → $15 |
| 5 July 2022 | Goldman Sachs | Maintains | Neutral | $28 → $14 |
| 21 Sept 2021 | Goldman Sachs | Upgrade | Neutral | $11 → $30 |
| 25 Nov 2020 | Baird | Maintains | Outperform | — |
| 25 Nov 2020 | Bank of America | Maintains | Neutral | — |
| 25 Nov 2020 | Barrington Research | Initiates | Outperform | — |
| 25 Nov 2020 | Credit Suisse | Downgrade | Neutral | — |
| 25 Nov 2020 | Goldman Sachs | Downgrade | Sell | — |
| 25 Nov 2020 | Morgan Stanley | Downgrade | Equal-Weight | — |
| 30 Apr 2020 | Goldman Sachs | Downgrade | Sell | — |
| 5 June 2019 | Morgan Stanley | Downgrade | Equal-Weight | $8.00 → $3.00 |
| 8 Nov 2018 | Baird | Maintains | Outperform | $10 → $8.00 |
| 30 July 2018 | Baird | Maintains | Outperform | $12 → $10 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ATTO.
This page is one stock. Monday covers all of them.
ATTO appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ATTO vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ATTO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 479.3×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 1% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −36.7%
- Dividend yield
- —
Higher than 12% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Attovia Therapeutics, Inc. has a market value of $690.3M and an enterprise value of $298.2M.
Attovia Therapeutics, Inc. employs 50 people.
Data provided by Twelve Data
ATTO and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ATTO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Attovia Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ATTO
What is the ATTO stock price forecast for 2026-2027?
The median 12-month analyst price target for Attovia Therapeutics, Inc. is $45, with estimates ranging from $34 to $52. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ATTO stock a buy right now?
Of the 5 analysts covering Attovia Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Attovia Therapeutics, Inc. 4 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ATTO?
As at 21 Nov 2026, Attovia Therapeutics, Inc. ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (49 of 100).
Will ATTO stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts is $45, and Ticker Nerd's factor model ranks Attovia Therapeutics, Inc. 4 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ATTO stock forecast for 2030?
No analyst covering Attovia Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ATTO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $34 to $52 over the next 12 months.
What does Attovia Therapeutics, Inc. do?
Attovia Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing precision biologics for immune-mediated diseases. The company’s core work centers on its ATTOBODY platform, which is designed to create multispecific protein therapies that target multiple disease pathways involved in inflammation and immune dysfunction.
About Attovia Therapeutics, Inc.
Attovia Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing precision biologics for immune-mediated diseases. The company’s core work centers on its ATTOBODY platform, which is designed to create multispecific protein therapies that target multiple disease pathways involved in inflammation and immune dysfunction. Its current pipeline includes candidates for dermatology conditions such as atopic dermatitis and chronic pruritus, as well as gastroenterology and inflammatory disorders, including inflammatory bowel disease. Attovia Therapeutics Inc. develops therapeutic programs aimed at areas with significant unmet medical need, using a platform-based approach intended to improve specificity and broaden treatment options across several disease areas. The company is based in San Carlos, California.
CEO Mr. Tao Fu M.B.A., M.S. · 50 employees · United States · https://www.attovia.com